FDA Limits Use of Johnson & Johnson (JNJ)'s Nizoral Antifungal Drug on Safety Concerns
7/26/2013 8:26:33 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
The Food and Drug Administration said it would limit the use of Johnson & Johnson's antifungal medicine, Nizoral tablets, warning that it may cause severe liver injuries and adrenal gland problems, and lead to harmful drug interactions. The agency said it approved changes to the drug's label to address the new safety issues. As a result, Nizoral oral tablets should not be the initial treatment for any fungal infection.
Help employers find you! Check out all the jobs and post your resume.
comments powered by